November 19, 2024

MASLD Affects 42% of US Adults, Study Finds

A US-based study found Hispanic individuals had significantly higher metabolic dysfunction-associated steatotic liver disease prevalence at 47.0% compared to 40.7% in non-Hispanic whites, despite nearly half of all U.S. adults showing signs of fatty liver disease.

Conexiant

November 18, 2024

Supreme Court Blocks Xifaxan Generic Entry

Reuters

November 13, 2024

Air Pollution Tied to Head, Neck Cancers

The strongest correlation between PM2.5 exposure and head and neck cancer incidence occurred at a 5-year lag period, suggesting a potential temporal relationship between air pollution exposure and cancer development.

Conexiant

November 12, 2024

Why Early-Onset CRC Rising

Early-onset rates are projected to reach 11% of all colon cancer and 23% of rectal cancer cases by 2030.

Conexiant

November 07, 2024

Zinc: Missing Link in HE Management?

Study reveals stark survival contrast: cirrhotic patients with normal zinc levels showed 86% survival rate versus significantly poorer outcomes in zinc-deficient patients (35.56 ± 11.65 mcg/dL, P<.0001), suggesting a potentially modifiable risk factor in hepatic encephalopathy management.

Conexiant

November 05, 2024

TAVI Reduces GI Lesions, Bleeding in Heyde

Six months post-TAVI, GI lesion counts in Heyde syndrome patients fell by 68% — with 55% of typical angiodysplasias disappearing, offering a promising dual benefit for aortic stenosis and GI bleeding management.

Conexiant

November 05, 2024

UK Study Maps Fatty Acids' Cancer Impact

In a UK Biobank study of over 250,000 participants, higher plasma omega-6 levels showed stronger protective effects against cancer in women and younger adults, while omega-3's benefits were more pronounced in men and older adults—suggesting age and sex may be crucial factors in fatty acid metabolism and cancer prevention.

Conexiant

October 30, 2024

Five Medical Societies Unite on GLP-1 Guidelines

Leading medical societies released unified perioperative guidance that challenges the practice of universal GLP-1RA discontinuation, instead advocating for individualized risk assessment and shared decision-making to prevent treatment disruption where safely possible.

Conexiant

October 30, 2024

Company Launches Diagnostic Tool Targeting Peri-Implant Disease

Integral Dental introduces OraclePI, a groundbreaking diagnostic test for peri-implant disease, offering personalized care and vital insights into bacterial infections, aiming to improve patient outcomes and bridge oral and systemic health.

Conexiant